Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
Pharmacoepidemiology and Drug Safety|May 10, 2002
Variability in abciximab (ReoPro) prescribing: evidence based or budget driven?J E F Zwart-van Rijkom, H G M Leufkens, M L Simoons, et al.The American Journal of Psychiatry|August 2, 2001
Suicide risk in placebo-controlled studies of major depressionJ G Storosum, B J van Zwieten, W van den Brink, et al.Pharmacoeconomics|November 7, 2000
Differences in attitudes, knowledge and use of economic evaluations in decision-making in The Netherlands. The Dutch results from the EUROMET ProjectJ E Zwart-van Rijkom, H G Leufkens, J J Busschbach, et al.Thrombosis and Haemostasis|February 3, 1987
Treatment of hereditary protein C deficiency with stanozololA W Broekmans, J Conard, R G van Weyenberg, et al.Nederlands Tijdschrift Voor Geneeskunde|May 17, 2000
[Clinical evaluation of efficacy and adverse effects in the (European) registration of drugs: what does it mean for the doctor and patient?]P P Koopmans, P A de Graeff, B J van Zwieten-Boot, et al.British Journal of Haematology|October 31, 2002
The uptake of recombinant Factor VIII in the NetherlandsJ E F Zwart-van Rijkom, I Plug, F R Rosendaal, et al.Blood|May 1, 1988
Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiencyK A Bauer, A W Broekmans, R M Bertina, et al.International Journal of Cardiology|February 22, 2001
Costs and effects of combining stenting and abciximab (ReoPro) in daily practiceJ E Zwart-van Rijkom, O H Klungel, H G Leufkens, et al.Haemostasis|January 1, 1990
Interaction of the combined medication with the new low-molecular-weight heparinoid Lomoparan (Org 10172) and acenocoumarolJ C Stiekema, A de Boer, M Danhof, et al.British Medical Journal (Clinical Research Ed.)|February 2, 1985
Cerebral haemorrhagic infarction in young patients with hereditary protein C deficiency: evidence for "spontaneous" cerebral venous thrombosisA R Wintzen, A W Broekmans, R M Bertina, et al.Pageof 3